Showing 2211-2220 of 2494 results for "".
- Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseaseshttps://modernod.com/news/opus-genetics-hosts-inaugural-patient-advocacy-outreach-webinar-on-inherited-retinal-diseases/2481058/Opus Genetics announced the release of the first patient advocacy outreach webinar featuring presentations by Opus leadership: Ben Yerxa, PhD, and CEO of Opus; Ash Jayagopal, PhD, and chief scientific officer; Joe Schachle, COO; and Jennifer Hunt, chief development officer. The recorded webinar,
- iTrack Canaloplasty to be Featured at the 2022 ESCRS Annual Meetinghttps://modernod.com/news/itrack-canaloplasty-to-be-featured-at-the-2022-escrs-annual-meeting/2481051/Nova Eye Medical announced that the company’s proprietary canaloplasty technology platform (iTrack™ and iTrack™ Advance) will be featured during the official scientific program of the European Society of Cataract and Refractive Surgeons (ESCRS) 40th Congress on Septemb
- Heidelberg Engineering and AI Software Partners Present Workflow Solution for Ophthalmic Analytics at EURETINA and ESCRShttps://modernod.com/news/heidelberg-engineering-and-ai-software-partners-present-secure-workflow-solution-for-ophthalmic-analytics-at-euretina-and-escrs/2481050/Heidelberg Engineering is expanding its healthcare IT portfolio with the introduction of Heidelberg AppWay. This latest addition to the company’s ecosystem offers secure access to ophthalmic software analytics and AI-powered support systems, according to Heidelberg. It will be embedded into
- Alcon to Acquire Aerie Pharmaceuticalshttps://modernod.com/news/alcon-to-acquire-aerie-pharmaceuticals/2481041/In another move to bolster its glaucoma portolio and expand its pharmaceutical offerings, Alcon announced it is acquiring Aerie Pharmaceuticals for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s lastest closing price. The transaction was a
- BVI Installs First Beyeonics One Systemhttps://modernod.com/news/bvi-installs-first-beyeonics-one-system/2481035/BVI announced that the first Beyeonics One System has been installed at Holzman Solomon Vision Partners, in McClean, Virginia. On August 17, Jonathon Solomon, MD, was the first US surgeon to offer ophthalmic surgery with the Beyeonics One platform in private practice. Under th
- Alcon’s Sue-Jean Lin Named 2022 US National CIO of the Yearhttps://modernod.com/news/alcons-sue-jean-lin-named-2022-us-national-cio-of-the-year/2481019/Alcon announced that Sue-Jean Lin, Senior Vice President and Chief Information and Transformation Officer, was awarded the 2022 U.S. National CIO of the Year ORBIE Award in the "Global" category for multinational companies over $5 billion in annual revenue. This follows her recognition
- Study: Neurolenses Have Significant Impact on Reading Speedhttps://modernod.com/news/neurolenses-have-significant-impact-on-reading-speed/2481017/As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader population focused on visual performance and producti
- American Academy of Optometry Launches Nationwide Search for New CEOhttps://modernod.com/news/american-academy-of-optometry-launches-nationwide-search-for-new-ceo/2480968/The American Academy of Optometry (AAO) has formed a search committee to identify candidates for the position of Chief Executive Officer. Current Chief Financial Officer (CFO)/Deputy CEO Richard Jones will serve as Interim Chief Executive Officer throughout the search. Mr. Jones has more than 20
- Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabeticshttps://modernod.com/news/ocuphire-granted-new-us-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics/2480941/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330, for diabetic eye disease. In addition, a new publication supporting the nov
- Foundation Fighting Blindness Announces Leadership Changeshttps://modernod.com/news/foundation-fighting-blindness-announces-leadership-changes/2480924/The Foundation Fighting Blindness announced the promotions of Jason Menzo to chief executive officer of the Foundation, and Russell Kelley, PhD, MBA, to managing director of the Retinal Degeneration (RD) Fund, the venture arm of the Foundation, effective Ju